Regeneron Pharmaceuticals, Inc.

Marine Prissette

Brian Zambrowicz

Matthew Koss

David Frendewey

Wen Fury

Arijit Bhowmick

Mathieu Desclaux

Claudia Racioppi

John R McWhirter

Andrew J Murphy

Lynn Macdonald

Ka-Man Venus Lai

Vera Voronina

Gustavo Droguett

Yu Bai

John Mcwhirter

Ashok Badithe

Cas-protein-ready tau biosensor cells, CRISPR/Cas synergistic activation mediator (SAM)-ready tau biosensor cells, and methods of making and using such cells to screen for genetic modifiers of tau seeding or aggregation are provided. Reagents and methods for sensitizing such cells to tau seeding activity or tau aggregation or for causing tau aggregation are also provided.

CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation

BANF1, PPP2CA, and ANKLE2 were identified as genes that promote tau aggregation when disrupted. Improved tauopathy models such as cells, tissues, or animals having mutations in or inhibition of expression of BANF1 and/or PPP2CA and/or ANKLE2 are provided. Methods of using such improved tauopathy models for assessing therapeutic candidates for the treatment of a tauopathy, methods of making the improved tauopathy models, and methods of accelerating or exacerbating tau aggregation in a tauopathy model are also provided.

Models of tauopathy

Methods and compositions are provided for generating antigen-binding proteins against a foreign antigen of interest.

Methods for producing antigen-binding proteins against foreign antigens

Cas-protein-ready tau bio sensor cells, CRISPR/Cas synergistic activation mediator (SAM)-ready tau biosensor cells, and methods of making and using such cells to screen for genetic vulnerability associated with tau aggregation are provided.

CRISPR/Cas dropout screening platform to reveal genetic vulnerabilities associated with tau aggregation

Growing community of inventors

Brooklyn, NY, United States of America

Marine Prissette